As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.
Three gene therapy contenders, Abeona, Fibrocell and Krystal, are taking different approaches in the quest to cure epidermolysis bullosa.
Sage Therapeutics looks to keep up momentum with SAGE-217 in bipolar depression, while Marinus tries to catch up with an oral postpartum depression project.
The failure of one of Allergan’s key pipeline projects puts the group’s chief executive under even more pressure.